Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
HCV
SVR12
children
direct-acting antivirals
meta-analysis
systematic review
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
revised:
13
10
2023
received:
17
07
2023
accepted:
18
12
2023
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
31
1
2024
Statut:
aheadofprint
Résumé
We evaluated the effectiveness and safety of pan-genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct-acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)-infected adolescents (12-18 years), older children (6-11 years), and young children (3-5 years). The purpose of this systematic review and meta-analysis was to inform the World Health Organization (WHO) guidelines. We included clinical trials and observational studies published up to August 11, 2021, that evaluated DAA regimens in HCV-infected adolescents, older children, and young children. We searched MEDLINE, EMBASE, and CENTRAL databases and key conference abstracts. Sustained virological response 12 weeks after the end of treatment (SVR12), adverse events (AEs), and treatment discontinuation were the outcomes evaluated. Risk of bias was assessed using a modified version of the ROBINS-I tool. Data were pooled using random-effects models, and certainty of the evidence was assessed using the GRADE approach. A total of 49 studies including 1882 adolescents, 436 older children, and 166 young children were considered. The SVR12 was 100% (95% Confidence Interval: 96-100), 96% (90-100), and 96% (83-100) for GLE/PIB in adolescents, older, and young children, respectively; 95% (90-99), 93% (86-98), and 83% (70-93), for SOF/VEL, respectively; and 100% (97-100) and 100% (94-100) for SOF/DCV in adolescent and older children, respectively. There was a clear trend towards a higher rate of any reported AE from adolescents (50%), older children (53%), to young children (72%). Serious AEs and treatment discontinuations were uncommon in adolescents and older children (<1%) but slightly higher in young children (3%). All three pan-genotypic DAA regimens were highly effective and well-tolerated and are now recommended by the WHO for use in adults, adolescents, and children down to 3 years, which will simplify procurement and supply chain management. The evidence was based largely on single-arm non-randomized controlled studies. Moreover, there were also missing data regarding key variables such as route of HCV acquisition, presence or absence of cirrhosis, or HIV co-infection that precluded evaluation of the impact of these factors on outcomes. CRD42020146752.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
We evaluated the effectiveness and safety of pan-genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct-acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)-infected adolescents (12-18 years), older children (6-11 years), and young children (3-5 years). The purpose of this systematic review and meta-analysis was to inform the World Health Organization (WHO) guidelines.
METHODS
METHODS
We included clinical trials and observational studies published up to August 11, 2021, that evaluated DAA regimens in HCV-infected adolescents, older children, and young children. We searched MEDLINE, EMBASE, and CENTRAL databases and key conference abstracts. Sustained virological response 12 weeks after the end of treatment (SVR12), adverse events (AEs), and treatment discontinuation were the outcomes evaluated. Risk of bias was assessed using a modified version of the ROBINS-I tool. Data were pooled using random-effects models, and certainty of the evidence was assessed using the GRADE approach.
RESULTS
RESULTS
A total of 49 studies including 1882 adolescents, 436 older children, and 166 young children were considered. The SVR12 was 100% (95% Confidence Interval: 96-100), 96% (90-100), and 96% (83-100) for GLE/PIB in adolescents, older, and young children, respectively; 95% (90-99), 93% (86-98), and 83% (70-93), for SOF/VEL, respectively; and 100% (97-100) and 100% (94-100) for SOF/DCV in adolescent and older children, respectively. There was a clear trend towards a higher rate of any reported AE from adolescents (50%), older children (53%), to young children (72%). Serious AEs and treatment discontinuations were uncommon in adolescents and older children (<1%) but slightly higher in young children (3%).
CONCLUSIONS
CONCLUSIONS
All three pan-genotypic DAA regimens were highly effective and well-tolerated and are now recommended by the WHO for use in adults, adolescents, and children down to 3 years, which will simplify procurement and supply chain management. The evidence was based largely on single-arm non-randomized controlled studies. Moreover, there were also missing data regarding key variables such as route of HCV acquisition, presence or absence of cirrhosis, or HIV co-infection that precluded evaluation of the impact of these factors on outcomes.
PROSPERO RECORD
UNASSIGNED
CRD42020146752.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
Pays : International
Informations de copyright
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 2021. Accessed August 23, 2022. https://www.who.int/publications/i/item/9789240027077
AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. AASLD/IDSA. Aasld-Idsa. 2021. Accessed August 23, 2022. https://www.hcvguidelines.org/
Pawlotsky J-M, Negro F, Aghemo A, et al. European Association for the Study of the liver (EASL) recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170-1218.
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477-487.
Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5:374-392.
Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. #909. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110.
Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. Hepatology 2020; 71: 31-43.
Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66:371-378.
Murray KF, Balistreri WF, Bansal S, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11. Hepatology. 2018;68:2158-2166.
Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C. Hepatology. 2020;71:422-430.
Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology. 2020;71:456-462.
Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, safety, and efficacy of Glecaprevir/Pibrentasvir in children with chronic HCV: part 2 of the DORA study. Hepatology. 2021;74:19-27.
Sokal E, Schwarz KB, Rosenthal P, et al. Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection in adolescents and children aged 3 to 17 years old through 24 weeks post-treatment. 2020. Accessed August 23, 2022. https://www.natap.org/2020/AASLD/AASLD_26.htm
Indolfi G, Kelly D, Nebbia G, et al. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with hepatitis C virus infection. Hepatology. 2022;76:445-455. doi:10.1002/HEP.32393
Gonzalez-Peralta, RP; Wirth, Squires, SRH; Baumann, U; Lang, T; Pawlowska M, Sluzewski, W; Majda-Stanislawska, E; Fischler, B; Balistreri, W; Jonas M, Xu, N; Rosenthal, P; Alkhouri, N; Romero, R; Benner, J; Grandhi, A; Castronuovo P, Haber, C; Caro, L; Haber B. Development of a Novel Model to Support Elbasvir/Grazoprevir Use in Children With Chronic Hepatitis C Virus Genotypes 1 or 4 Infection [abstract LP10]. American Association for the Study of Liver Diseases (AASLD) Liver Meeting. 2019.
Leung DH, Wirth S, Yao BB, et al. Ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4. Hepatol Commun. 2018;2:1311-1319.
Rosenthal P, Narkewicz MR, Yao BB, et al. Ombitasvir, paritaprevir, ritonavir, and dasabuvir mini-tabs plus ribavirin for children aged 3-11 years with hepatitis C genotype 1a. Adv Ther. 2020;37:3299-3310.
Indolfi G, Serranti D, Bettiol A, et al. Efficacy and safety of direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in children and adolescents: a systematic review and meta-analysis. PROSPERO 2020 CRD42020146752. 2020. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020146752
Indolfi G, Giometto S, Serranti D, et al. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2020;52:52-1133. doi:10.1111/apt.16037
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:335. doi:10.1136/bmj.i4919
Package ‘meta’ Title General Package for Meta-Analysis. 2019. doi:10.1007/978-3-319-21416
Zoratti MJ, Siddiqua A, Morassut RE, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. doi:10.1016/j.eclinm.2019.12.007
Oxman AD. Grading quality of evidence and strength of recommendations. Br Med J. 2004;328:1490. doi:10.1136/bmj.328.7454.1490
Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18:e1230.
Al-Kaaby BA, Al-Ethawi AES. The effectiveness of oral antiviral (sofosbuvir/ledipasvir) in treating children with HCV infection. Pak J Med Sci. 2018;34:1353-1356.
Hashmi MA, Cheema HA. Effectiveness and safety of sofosbuvir in treatment-Näive children with hepatitis C infection. J Coll Physicians Surg Pak. 2017;27:423-426.
Behairy BE, El-Araby HA, El-Guindi MA, et al. Safety and efficacy of 8 weeks ledipasvir/sofosbuvir for chronic hepatitis C genotype 4 in children aged 4-10 years. J Pediatr. 2020;219:106-110.
Dhiman RK, Grover GS, Premkumar M, et al. Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: the public health perspective. J Pediatr Gastroenterol Nutr. 2019;68:74-80.
El-Araby HA, Behairy BE, El-Guindi MA, et al. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents. Hepatol Int. 2019;13:706-714.
El-Baraky IA, Abbassi MM, Ebied FS, Hassany M, Sabry NA, El-Sayed MH. Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in hepatitis C virus infected adolescent patients. Clin Res Hepatol Gastroenterol. 2021;45:101747.
El-Karaksy H, Mogahed EA, Abdullatif H, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67:626-630.
El-Khayat HR, Kamal EM, El-Sayed MH, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018;47:838-844.
El-Khayat H, Kamal EM, Yakoot M, et al. Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. Eur J Gastroenterol Hepatol. 2019;31:1004-1009.
El-Khayat H, Yakoot M, El-Shabrawi M, Fouad Y, Attia D, Kamal EM. Treatment of chronic hepatitis C in adolescent patients with positive HBsAg or with occult hepatitis B: is the risk of hepatitis B reactivation significant? Pediatr Infect Dis J. 2021;40:11-15.
El-Shabrawi MH, Abdo AM, El-Khayat HR, Yakoot M. Shortened 8 weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;66:425-427.
El-Shabrawi MHF, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad MMAH, Yakoot M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children. Aliment Pharmacol Ther. 2018;47:1699-1704.
El-Shabrawi MH, Sherief LM, Yakoot M, et al. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases. 2019;7:2247-2255.
El-Shabrawi M, Baroudy S, Hassanin F, Behairy AS, Yakoot M, Ahmed A. Follow-up of chronic paediatric hepatitis C virus in a low−/middle-income country. Acta Paediatr Int J Paediatr. 2020;109:2699-2705.
Fouad HM, Ahmed Mohamed A, Sabry M, Abdel Aziz H, Eysa B, Rabea M. The effectiveness of ledipasvir/sofosbuvir in youth with genotype 4 hepatitis C virus: a single Egyptian center study. Pediatr Infect dis J. 2019;38:22-25.
Fouad HM, Sabry MA, Ahmed A, Hassany M, Al Soda MF, Aziz HA. Generic ledipasvir-sofosbuvir treatment for adolescents with chronic hepatitis C virus infection. J Pediatric Infect dis Soc. 2020;9:386-389.
Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat. 2019;26:263-270.
Kamal EM, El-Shabrawi M, El-Khayat H, et al. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver Int. 2020;40:319-323.
Makhlouf NA, Abdelmalek MO, Ibrahim ME, Abu-Faddan NH, Kheila AE, Mahmoud AA. Ledipasvir/sofosbuvir in adolescents with chronic hepatitis C genotype 4 with and without hematological disorders: virological efficacy and impact on liver stiffness. J Pediatric Infect Dis Soc. 2021;10:7-13.
Mehta R, Kabrawala M, Nandwani S, et al. Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with β-thalassemia major. J Clin Exp Hepatol. 2018;8:3-6.
Mogahed EA, El-Karaksy H, Abdullatif H, et al. Improvement in liver stiffness in pediatric patients with hepatitis C virus after treatment with direct acting antivirals. J Pediatr. 2021;233:126-131.
Nagral A, Jhaveri A, Sawant S, et al. Treatment of chronic hepatitis C infection with direct acting antivirals in adolescents with thalassemia major. Indian J Pediatr. 2019;86:148-153.
Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and safety of direct acting antiviral therapy for chronic hepatitis C in thalassemic children. J Pediatr Hematol Oncol. 2018;40:511-514.
Serranti D, Nebbia G, Cananzi M, et al. Efficacy of sofosbuvir/ledipasvir in adolescents with chronic hepatitis C genotypes 1, 3, and 4: a real-world study. J Pediatr Gastroenterol Nutr. 2021;72:95-100.
Yakoot M, El-Shabrawi MH, Abdelgawad MM, et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;67:86-89.
El-Sayed MH, Kabil K, Ebeid F, et al. #OS-2306. DAA therapy in HCV-infected Egyptian children: real-life model from a multicentre program supported by an NGO. Presented at EALS 2021.
Hirsch C, Badue Pereira MF, Bernardes T, et al. #P0824/#2279. Direct-acting antivirals for children with chronic hepatitis C: a BRAZILIAN single center experience. Presented at ESPID 2020.
Sheha G, Elsayed R, Elbasiony M, Mikhail N. Ledipasvir 90 mg/sofosbuvir 400 mg for treatment of children with CHC genotype 4: single Centre experience (abstr). J Hepatol. 2018;68:S267.
Bansal S, Pawłowska M, Nebbia G, et al. Safety and efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in adoloscents with chronic hepatitis C virus infection. The Liver Meeting. Digital Experience. AASLD. November 13-16-2020. 2020. Accessed August 23, 2022. https://www.natap.org/2020/AASLD/AASLD_25.htm
Wirth S, Gonzalez-Peralta RP, Squires RH, et al. Elbasvir/Grazoprevir in children aged 3 to <18 years with chronic hepatits C virus (HCV) genotype (GT) 1 or 4 infection: final results from an iterative pharmacokinetic (PK) modeling study. 2020; 909.
Ahmed M, Hanno A, Hamouda S, Abdelgawad M, Abouelkhier H. Comparison between safety and efficacy of two treatment regimens for pediatric patients with chronic hepatitis C virus: sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimen (abstr). J Hepatol. 2019;70:e208.
El-Sayed M, Hassany M, Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus infection (abstr). J Hepatol. 2017;66:S178.
El-Sayed MH, Hassany M, Ebeid FSES, Zeidan A, Asem N. Ledipasvir/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non-cirrhotic children and adolescents (abstr). J Hepatol. 2019;70:e221.
El-Sayed MH, Ebeid FSES, Zekri AR, et al. Ledipasvir/sofosbuvir for 12 weeks is safe and effective in adolescents with chronic hepatitis C virus infection and hematological malignancies undergoing chemotherapy (abstr). J Hepatol. 2018;68:S515.
Gill ML. Outcomes of sofosbuvir and ribavirin treatment combination in HEP C G3 pediatric patients (abstr). Hepatol Int. 2018;12:S515.
Hassan A, Bughio U, Bhatti R, Ali M, Jamali L, Muhammad S. Safety and efficacy of sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir with or without ribavirin combinations in children and adolescents with chronic hepatitis C (abstr). Am J Gastroenterol. 2019;114:S592.
Mahmud S, Gulshan J, Shafi AS. Effectiveness and safety of sofosbuvir in chronic hepatitis C virus infection of Bangladeshi children (abstr). J Pediatr Gastroenterol Nutr. 2021;72:950-951.
Megahed A, el Latief Alsayed MA, el Zainy S, Zalata K, el Mabood SA. Hepatic involvement and HCV status among Egyptian children with Gaucher disease (abstr). J Pediatr Gastroenterol Nutr. 2021;72:957.
Patel R, Poddar P, Chaubal A, Pandey V, Ingle M, Sawant P; Safety and efficacy of Sofosbuvir (SOF), Ledipasvir (LDV) and daclatasvir (DCT) in thalassemic patients with chronic hepatitis C: a single center experience (abstr). Indian J Gastroenterol 2016; 35: LVH-07.
WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018. Accessed August 23, 2022. https://www.who.int/publications/i/item/9789241550345
AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect dis. 2018;67:1477-1492.
Indolfi G, Giometto S, Serranti D, et al. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2020;52:52-1133. doi:10.1111/apt.16037
Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol (Australia). 2008;23:226-230. doi:10.1111/j.1440-1746.2007.04859.x
Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009;48:341-347. doi:10.1097/MPG.0b013e318185998f
Tehranian S, Jafari S, Yousofi J, et al. Health-related quality of life (HRQOL) in children with chronic liver disease in North East Iran using PedsQL™ 4.0. Electron Physician. 2015;7:1214-1219. doi:10.14661/2015.1214-1219
Younossi ZM, Stepanova M, Balistreri W, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr. 2018;66:112-116.
Younossi ZM, Stepanova M, Schwarz KB, et al. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat. 2018;25:354-362.
Nguyen J, Barritt AS, Jhaveri R. Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C virus infection. J Pediatr. 2019;207:90-96. doi:10.1016/j.jpeds.2018.12.012
Cressey TR, Abbassi M, Lallemant M, et al. Effective and safe daclatasvir drug exposures predicted in children using adult formulations. Pediatr Infect Dis J. 2021;40:1081-1086. doi:10.1097/inf.0000000000003282
Hirsch CB, Pereira MFB, Benevides GN, et al. Hepatitis C in children and adolescents of a Brazilian tertiary center: identifying patients eligible for direct-acting antivirals. Pediatr Infect Dis J. 2020;39:E276-E278.
Indolfi G, Kelly D, Nebbia G, et al. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Hepatology. 2022;76:445-455.
Gonzalez-Peralta RP, Wirth S, Squires RH, et al. Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study. Hepatol Commun. 2023;7:e0031.
El-Sayed MH, Ebeid FSE, Zekri AR, et al. Ledipasvir-sofosbuvir in adolescents with chronic hepatitis C and hematological malignancies undergoing chemotherapy. J Pediatr Gastroenterol Nutr. 2022;74:626-630.
Malik F, Bailey H, Chan P, et al. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. JHEP Rep. 2021;3:100227. doi:10.1016/J.JHEPR.2021.100227